• Mashup Score: 0
    When Dying Patients Want Unproven Drugs - 2 year(s) ago

    Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.

    Source: The New Yorker
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of Eddie_Cliff
      Eddie_Cliff

      Must-read, critically important article @NewYorker on drug regulation, patients & the FDA “If the crusade for access wasn’t accompanied by a commensurately spirited campaign for answers, the chief beneficiaries would be the pharmaceutical companies.” https://t.co/sqoM4wWpcj

  • Mashup Score: 4
    When Dying Patients Want Unproven Drugs - 2 year(s) ago

    Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.

    Source: The New Yorker
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESchattner
      ESchattner

      This part resonates. “Please do not let another generation of A.L.S. patients die in pursuit of the perfect,” said Brian Wallach. "Scientific certainty was a luxury that only the healthy could afford." https://t.co/ES8K0cyyjG #patientadvocacy #drugaccess #FDA @iamalsorg

    • Profile photo of ESchattner
      ESchattner

      I don't agree with the spin of this @NewYorker piece on the FDA and investigational drug access. Among a host of issues, the repeated citation of @akesselheim, who figures "only about a fifth of approved drugs ever showed a meaningful impact on survival." https://t.co/ES8K0cyyjG

  • Mashup Score: 7
    When Dying Patients Want Unproven Drugs - 2 year(s) ago

    Patient-advocacy groups mobilized to demand access to a controversial new drug called Relyvrio. But hasty approval comes at a cost.

    Source: The New Yorker
    Categories: HIV/AIDS, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of gregggonsalves
      gregggonsalves

      This @NewYorker story walks a fine line in trying to articulate the trade-offs in the key dilemma, of access vs. answers, in the development of approval of new drugs. @akesselheim @jsross119 @gwenpetersen7 @alsadvocacy @MeritCudkowicz @ALSProbSolvers https://t.co/4cVUc0FqGH

  • Mashup Score: 0
    What if We’re Thinking About Inflation All Wrong? - 2 year(s) ago

    Isabella Weber’s heterodox ideas about government price controls are transforming policy in the United States and across Europe.

    Source: The New Yorker
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of pash22
      pash22

      What if We’re Thinking About Inflation All Wrong? @IsabellaMWeber ’s heterodox ideas about government price controls are transforming policy in the United States and across Europe. https://t.co/5LI4bdw69a via @zachdcarter

Load More